Find information on Cannabis Use Disorder diagnosis, including clinical documentation, ICD-10-CM coding (C and F codes), DSM-5 criteria, Marijuana Use assessment, and THC Use treatment options. Learn about healthcare best practices for cannabis-related diagnoses and improve your medical coding accuracy. This resource provides valuable insights for clinicians, healthcare professionals, and medical coders dealing with substance use disorders.
Also known as
Cannabis-related disorders
Covers cannabis use disorders, including dependence and harmful use.
Unspecified cannabis-related disorder
Used when a more specific cannabis-related diagnosis is not available.
Tobacco use
While not directly cannabis, can be used if cannabis is used with tobacco.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the cannabis use disorder?
When to use each related code
| Description |
|---|
| Cannabis use disorder. |
| Cannabis intoxication. |
| Cannabis withdrawal. |
Coding cannabis use without specifying type (abuse, dependence, etc.) leads to inaccurate severity and reimbursement.
Failing to capture co-occurring mental health or physical conditions associated with cannabis use impacts quality reporting.
Insufficient documentation of cannabis use frequency, duration, and impact on function hinders accurate coding and audit defense.
Q: What are the most effective evidence-based screening tools for cannabis use disorder (CUD) in adolescents during a routine clinical visit?
A: Several validated screening tools can effectively identify cannabis use disorder (CUD) in adolescents. The CRAFFT (Car, Relax, Alone, Forget, Friends, Trouble) is a brief, validated screening tool specifically designed for adolescents. It assesses six domains related to substance use. The ASSIST (Alcohol, Smoking and Substance Involvement Screening Test) is another option that screens for a broader range of substance use, including cannabis. Additionally, incorporating the DSM-5 criteria for CUD into a clinical interview can provide a comprehensive assessment. This involves inquiring about frequency of use, cravings, impairment in functioning, and withdrawal symptoms. Explore how integrating these screening tools into your workflow can enhance early identification and intervention for CUD. Consider implementing routine screening as part of standard adolescent healthcare.
Q: How do I differentiate between cannabis-induced psychosis and a primary psychotic disorder in a young adult presenting with new-onset psychotic symptoms?
A: Differentiating between cannabis-induced psychosis and a primary psychotic disorder like schizophrenia can be challenging in young adults. A thorough clinical history is crucial, focusing on the timeline of symptom onset concerning cannabis use. If psychotic symptoms predate cannabis use or persist significantly beyond periods of abstinence (typically weeks to months), a primary psychotic disorder is more likely. Assess for a family history of psychotic illness, which increases the risk of primary psychosis. Cognitive testing can also be helpful, as cognitive deficits are often more pronounced in primary psychotic disorders. Furthermore, consider monitoring symptom resolution during a period of monitored abstinence. Learn more about the diagnostic criteria for both cannabis-induced psychosis and primary psychotic disorders to aid in accurate diagnosis and appropriate treatment planning.
Patient presents with symptoms consistent with cannabis use disorder, also known as marijuana use disorder or THC use disorder. The patient reports regular cannabis use, exhibiting signs of increased tolerance, withdrawal symptoms upon cessation, and continued use despite negative consequences. Assessment includes a detailed substance use history, including frequency, quantity, method of ingestion (e.g., smoking, vaping, edibles), and duration of use. The patient's reported symptoms include craving, irritability, anxiety, sleep disturbances, decreased appetite, and difficulty concentrating. Physical examination may reveal conjunctival injection, increased heart rate, and dry mouth. Differential diagnoses considered include other substance use disorders, anxiety disorders, and mood disorders. The patient's cannabis use meets the DSM-5 criteria for cannabis use disorder, moderate severity. Treatment plan includes motivational interviewing, cognitive behavioral therapy (CBT) for substance abuse, and referral to support groups for cannabis cessation. Patient education on the risks associated with continued cannabis use, including potential respiratory issues, cardiovascular complications, and mental health implications, was provided. Follow-up appointment scheduled to monitor progress and adjust treatment as needed. ICD-10 code F12.20 will be used for billing and coding purposes. Continued monitoring and support are crucial for successful cannabis cessation and relapse prevention.